Medtronic (MDT) Competitors

$74.56 -1.59 (-2.09%)

Closing price 03:59 PM Eastern

Extended Trading

$74.85 +0.29 (+0.39%)

As of 07:29 PM Eastern

MDT vs. DXCM, GEHC, ISRG, ABT, and BSX

Should you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include DexCom (DXCM), GE HealthCare Technologies (GEHC), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), and Boston Scientific (BSX). These companies are all part of the "medical" sector.

How does Medtronic compare to DexCom?

DexCom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	4.91	$836.30M	$2.34	25.35
Medtronic	$33.54B	2.85	$4.66B	$3.59	20.77

97.8% of DexCom shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Medtronic had 23 more articles in the media than DexCom. MarketBeat recorded 45 mentions for Medtronic and 22 mentions for DexCom. DexCom's average media sentiment score of 1.19 beat Medtronic's score of 1.17 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	14 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Medtronic	33 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

DexCom presently has a consensus target price of $83.50, indicating a potential upside of 40.74%. Medtronic has a consensus target price of $107.80, indicating a potential upside of 44.58%. Given Medtronic's higher probable upside, analysts plainly believe Medtronic is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Medtronic	0 Sell rating(s)	11 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.58

DexCom has a net margin of 19.31% compared to Medtronic's net margin of 13.00%. DexCom's return on equity of 33.33% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Medtronic	13.00%	14.82%	7.88%

DexCom has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Summary

DexCom beats Medtronic on 12 of the 17 factors compared between the two stocks.

How does Medtronic compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Medtronic pays an annual dividend of $2.84 per share and has a dividend yield of 3.8%. GE HealthCare Technologies pays out 3.3% of its earnings in the form of a dividend. Medtronic pays out 79.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GE HealthCare Technologies has increased its dividend for 1 consecutive years and Medtronic has increased its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Medtronic has higher revenue and earnings than GE HealthCare Technologies. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.36	$2.08B	$4.18	14.76
Medtronic	$33.54B	2.85	$4.66B	$3.59	20.77

82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 0.3% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Medtronic had 38 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 45 mentions for Medtronic and 7 mentions for GE HealthCare Technologies. Medtronic's average media sentiment score of 1.17 beat GE HealthCare Technologies' score of 0.39 indicating that Medtronic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medtronic	33 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

GE HealthCare Technologies currently has a consensus target price of $80.67, indicating a potential upside of 30.74%. Medtronic has a consensus target price of $107.80, indicating a potential upside of 44.58%. Given Medtronic's stronger consensus rating and higher possible upside, analysts plainly believe Medtronic is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Medtronic	0 Sell rating(s)	11 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.58

Medtronic has a net margin of 13.00% compared to GE HealthCare Technologies' net margin of 9.10%. GE HealthCare Technologies' return on equity of 20.46% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Medtronic	13.00%	14.82%	7.88%

GE HealthCare Technologies has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Summary

Medtronic beats GE HealthCare Technologies on 13 of the 18 factors compared between the two stocks.

How does Medtronic compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Intuitive Surgical has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Intuitive Surgical has a net margin of 28.15% compared to Medtronic's net margin of 13.00%. Intuitive Surgical's return on equity of 15.98% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
Medtronic	13.00%	14.82%	7.88%

Intuitive Surgical presently has a consensus target price of $581.91, indicating a potential upside of 38.53%. Medtronic has a consensus target price of $107.80, indicating a potential upside of 44.58%. Given Medtronic's higher probable upside, analysts clearly believe Medtronic is more favorable than Intuitive Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.65
Medtronic	0 Sell rating(s)	11 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.58

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 0.3% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Medtronic had 9 more articles in the media than Intuitive Surgical. MarketBeat recorded 45 mentions for Medtronic and 36 mentions for Intuitive Surgical. Intuitive Surgical's average media sentiment score of 1.51 beat Medtronic's score of 1.17 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	30 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Very Positive
Medtronic	33 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Medtronic has higher revenue and earnings than Intuitive Surgical. Medtronic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.58B	14.06	$2.86B	$8.25	50.92
Medtronic	$33.54B	2.85	$4.66B	$3.59	20.77

Summary

Intuitive Surgical beats Medtronic on 12 of the 16 factors compared between the two stocks.

How does Medtronic compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Abbott Laboratories currently has a consensus price target of $119.43, indicating a potential upside of 44.63%. Medtronic has a consensus price target of $107.80, indicating a potential upside of 44.58%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, research analysts clearly believe Abbott Laboratories is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Medtronic	0 Sell rating(s)	11 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Medtronic had 13 more articles in the media than Abbott Laboratories. MarketBeat recorded 45 mentions for Medtronic and 32 mentions for Abbott Laboratories. Medtronic's average media sentiment score of 1.17 beat Abbott Laboratories' score of 1.04 indicating that Medtronic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	20 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Medtronic	33 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Abbott Laboratories has a net margin of 13.90% compared to Medtronic's net margin of 13.00%. Abbott Laboratories' return on equity of 17.62% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
Medtronic	13.00%	14.82%	7.88%

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 3.1%. Medtronic pays an annual dividend of $2.84 per share and has a dividend yield of 3.8%. Abbott Laboratories pays out 70.6% of its earnings in the form of a dividend. Medtronic pays out 79.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has increased its dividend for 54 consecutive years and Medtronic has increased its dividend for 49 consecutive years.

Abbott Laboratories has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.24	$6.52B	$3.57	23.13
Medtronic	$33.54B	2.85	$4.66B	$3.59	20.77

Abbott Laboratories has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Abbott Laboratories beats Medtronic on 15 of the 20 factors compared between the two stocks.

How does Medtronic compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Boston Scientific has a net margin of 17.29% compared to Medtronic's net margin of 13.00%. Boston Scientific's return on equity of 19.17% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.29%	19.17%	10.77%
Medtronic	13.00%	14.82%	7.88%

Boston Scientific has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

In the previous week, Medtronic had 20 more articles in the media than Boston Scientific. MarketBeat recorded 45 mentions for Medtronic and 25 mentions for Boston Scientific. Medtronic's average media sentiment score of 1.17 beat Boston Scientific's score of 0.66 indicating that Medtronic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	13 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Medtronic	33 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Medtronic has higher revenue and earnings than Boston Scientific. Medtronic is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.61B	3.84	$2.90B	$2.39	22.31
Medtronic	$33.54B	2.85	$4.66B	$3.59	20.77

Boston Scientific currently has a consensus price target of $93.91, indicating a potential upside of 76.10%. Medtronic has a consensus price target of $107.80, indicating a potential upside of 44.58%. Given Boston Scientific's stronger consensus rating and higher possible upside, equities analysts clearly believe Boston Scientific is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.92
Medtronic	0 Sell rating(s)	11 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.58

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Boston Scientific beats Medtronic on 11 of the 16 factors compared between the two stocks.

Get Medtronic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDT vs. The Competition

Export

Metric	Medtronic	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$95.73B	$7.85B	$6.18B	$22.92B
Dividend Yield	3.73%	2.50%	2.78%	4.02%
P/E Ratio	20.77	16.79	20.66	28.92
Price / Sales	2.85	7.91	528.16	24.52
Price / Cash	9.83	17.15	27.81	19.21
Price / Book	1.98	3.51	9.77	4.65
Net Income	$4.66B	$223.05M	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-14.46%	38.64%	6.25%	3.95%
1 Year Performance	-10.68%	4.05%	41.74%	28.96%

Medtronic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDT Medtronic	4.9642 of 5 stars	$74.56 -2.1%	$107.80 +44.6%	-8.9%	$95.73B	$33.54B	20.77	95,000	Positive News
DXCM DexCom	4.7294 of 5 stars	$59.99 -2.2%	$83.50 +39.2%	-28.4%	$23.15B	$4.82B	25.64	11,000	Analyst Downgrade
GEHC GE HealthCare Technologies	4.8751 of 5 stars	$61.01 0.0%	$80.67 +32.2%	-9.2%	$27.75B	$20.98B	14.60	54,000
ISRG Intuitive Surgical	4.2734 of 5 stars	$452.21 -1.2%	$581.91 +28.7%	-16.1%	$160.15B	$10.06B	54.81	17,021	Positive News Analyst Revision
ABT Abbott Laboratories	4.9602 of 5 stars	$87.59 -2.1%	$119.43 +36.4%	-36.9%	$152.56B	$44.33B	24.53	115,000	Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MDT) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medtronic (MDT) Competitors

MDT vs. DXCM, GEHC, ISRG, ABT, and BSX

How does Medtronic compare to DexCom?

Summary

How does Medtronic compare to GE HealthCare Technologies?

Summary

How does Medtronic compare to Intuitive Surgical?

Summary

How does Medtronic compare to Abbott Laboratories?

Summary

How does Medtronic compare to Boston Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDT vs. The Competition

Medtronic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medtronic (MDT) Competitors

MDT vs. DXCM, GEHC, ISRG, ABT, and BSX

How does Medtronic compare to DexCom?

Which has better earnings and valuation, DXCM or MDT?

Do institutionals & insiders believe in DXCM or MDT?

Does the media favor DXCM or MDT?

Do analysts prefer DXCM or MDT?

Is DXCM or MDT more profitable?

Which has more volatility & risk, DXCM or MDT?

Summary

How does Medtronic compare to GE HealthCare Technologies?

Is GEHC or MDT a better dividend stock?

Which has preferable valuation & earnings, GEHC or MDT?

Do institutionals & insiders have more ownership in GEHC or MDT?

Does the media favor GEHC or MDT?

Do analysts rate GEHC or MDT?

Is GEHC or MDT more profitable?

Which has more volatility & risk, GEHC or MDT?

Summary

How does Medtronic compare to Intuitive Surgical?

Which has more risk & volatility, ISRG or MDT?

Is ISRG or MDT more profitable?

Do analysts recommend ISRG or MDT?

Do insiders and institutionals believe in ISRG or MDT?

Does the media favor ISRG or MDT?

Which has better valuation & earnings, ISRG or MDT?

Summary

How does Medtronic compare to Abbott Laboratories?

Do analysts rate ABT or MDT?

Does the media refer more to ABT or MDT?

Is ABT or MDT more profitable?

Is ABT or MDT a better dividend stock?

Which has preferable valuation and earnings, ABT or MDT?

Which has more risk and volatility, ABT or MDT?

Do institutionals and insiders believe in ABT or MDT?

Summary

How does Medtronic compare to Boston Scientific?

Is BSX or MDT more profitable?

Which has more risk and volatility, BSX or MDT?

Does the media favor BSX or MDT?

Which has preferable valuation and earnings, BSX or MDT?

Do analysts rate BSX or MDT?

Do insiders and institutionals have more ownership in BSX or MDT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDT vs. The Competition

Medtronic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools